Search
bococizumab
Not yet FDA-approved.
Indications:
- high-risk cardiovascular disease*
* no benefit in lower-risk patients
Dosage:
- 150 mg SQ every 2 weeks [2]
Adverse effects:
- antidrug antibodies markedly diminish magnitude & durability of LDL cholesterol reduction [1]
Mechanism of action:
- PCSK9 inhibitor, fully humanized monoclonal antibody
Interactions
drug adverse effects of anti-hyperlipidemic agents
General
PCSK9 inhibitor (ALN-PCS)
pharmaceutical monoclonal antibody
References
- Ridker PM, Tardif JC, Amarenco P, et al.
Lipid-reduction variability and antidrug-antibody formation
with bococizumab.
N Engl J Med 2017 Mar 17
PMID: 28304227
- Ridker PM, Revkin J, Amarenco P
Cardiovascular Efficacy and Safety of Bococizumab in High-
Risk Patients.
N Engl J Med. 2017 Mar 17 -> 376:1527-1539. April 20, 2017
http://www.nejm.org/doi/full/10.1056/NEJMoa1701488
PMID: 28304242 Free full text